These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33124584)

  • 1. Recent Advances in the Pharmacology of Tardive Dyskinesia.
    Caroff SN
    Clin Psychopharmacol Neurosci; 2020 Nov; 18(4):493-506. PubMed ID: 33124584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.
    Zai CC; Tiwari AK; Mazzoco M; de Luca V; Müller DJ; Shaikh SA; Lohoff FW; Freeman N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL
    J Psychiatr Res; 2013 Nov; 47(11):1760-5. PubMed ID: 24018103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
    Golsorkhi M; Koch J; Pedouim F; Frei K; Bondariyan N; Dashtipour K
    Tremor Other Hyperkinet Mov (N Y); 2024; 14():13. PubMed ID: 38497033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.
    Dorfman BJ; Jimenez-Shahed J
    Expert Rev Neurother; 2021 Jan; 21(1):9-20. PubMed ID: 33174440
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetics of tardive dyskinesia: Promising leads and ways forward.
    Zai CC; Maes MS; Tiwari AK; Zai GC; Remington G; Kennedy JL
    J Neurol Sci; 2018 Jun; 389():28-34. PubMed ID: 29502799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management.
    Sreeram V; Shagufta S; Kagadkar F
    Cureus; 2019 Aug; 11(8):e5471. PubMed ID: 31641566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine depleters in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Expert Opin Pharmacother; 2016 Dec; 17(18):2461-2470. PubMed ID: 27819145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement-based Diagnosis and Treatment for Tardive Dyskinesia.
    Correll CU; Citrome L
    J Clin Psychiatry; 2021 Aug; 82(5):. PubMed ID: 34464521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Tardive Dyskinesia.
    Bashir HH; Jankovic J
    Neurol Clin; 2020 May; 38(2):379-396. PubMed ID: 32279716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new era in the diagnosis and treatment of tardive dyskinesia.
    Caroff SN
    CNS Spectr; 2022 Oct; ():4-14. PubMed ID: 36278439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.
    El-Sayeh HG; Rathbone J; Soares-Weiser K; Bergman H
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD000458. PubMed ID: 29342497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valbenazine in the treatment of tardive dyskinesia.
    Witek N; Comella C
    Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tardive dyskinesia: Who gets it and why.
    Frei K
    Parkinsonism Relat Disord; 2019 Feb; 59():151-154. PubMed ID: 30522959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation.
    Farber RH; Stull DE; Witherspoon B; Evans CJ; Yonan C; Bron M; Dhanda R; Jen E; Brien CO'
    J Patient Rep Outcomes; 2024 Jan; 8(1):2. PubMed ID: 38175450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future directions in tardive dyskinesia research.
    Meyer JM
    J Neurol Sci; 2018 Jun; 389():76-80. PubMed ID: 29433809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment of tardive dyskinesia.
    Margolius A; Fernandez HH
    Parkinsonism Relat Disord; 2019 Feb; 59():155-160. PubMed ID: 30591350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.